tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Cory Kasimov, 49 are a HOLD (25.65%), 142 are a BUY (74.35%).
Analyst Cory Kasimov, currently employed at EVERCORE, carries an average stock price target met ratio of 62.72% that have a potential upside of 35.08% achieved within 314 days.
Cory Kasimov’s has documented 367 price targets and ratings displayed on 42 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on RVMD, Revolution Medicines at 27-Aug-2026.
Analyst best performing recommendations are on GBT (GLOBAL BLOOD THERAPEUTICS).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 23-Jun-2025
$36
$16.88 (88.28%)
$37
11 days ago
(08-Oct-2026)
1/10 (10%)
$16.42 (83.86%)
173
Buy Since 15-Dec-2025
$33
$13.88 (72.59%)
$37
24 days ago
(25-Sep-2026)
0/3 (0%)
$12.32 (59.57%)
Buy Since 17-Apr-2025
$34
$14.88 (77.82%)
$36
24 days ago
(25-Sep-2026)
4/6 (66.67%)
$13.32 (64.41%)
144
Buy Since 25-Sep-2025
$31
$11.88 (62.13%)
$38
24 days ago
(25-Sep-2026)
1/4 (25%)
$10.32 (49.90%)
831
Buy Since 28-Feb-2024
$35
$15.88 (83.05%)
$41
24 days ago
(25-Sep-2026)
9/15 (60%)
$14.32 (69.25%)
393
Which stock is Cory Kasimov most bullish on?
Which stock is Cory Kasimov most reserved on?
What Year was the first public recommendation made by Cory Kasimov?
